KWF funding for our long-standing cancer phosphoproteomics research!
- Post by: OPL
- July 20, 2025
- Comments off
In this project, we will identify biomarkers to aid individualized multi-kinase inhibitor (MKI) therapy selection in patients with metastatic renal and thyroid cancer. Multiple MKIs are standard-of-care in these cancer types. However, no predictive biomarkers are available to guide their selection and prevent toxicity of ineffective treatment. Profiling of cancer cell lines annotated for drug response and patient samples annotated for clinical response, together with kinase activity scoring using our INKA pipeline and machine learning, will enable to develop a predictor for drug response. When successful, this project will pave the way for a phosphoproteome profile-guided clinical trial aiming to give the right multi-kinase inhibitor to the right patient.